BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15367563)

  • 1. Excitement tempered by long road ahead for dendritic cell vaccines.
    Vanchieri C
    J Natl Cancer Inst; 2004 Sep; 96(18):1350-1. PubMed ID: 15367563
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer vaccine strategies get bigger and better.
    de Gruijl TD; Curiel DT
    Nat Med; 1999 Oct; 5(10):1124-5. PubMed ID: 10502808
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic cancer vaccines.
    Morris LF; Ribas A
    Surg Oncol Clin N Am; 2007 Oct; 16(4):819-31, ix. PubMed ID: 18022546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):67. PubMed ID: 16227966
    [No Abstract]   [Full Text] [Related]  

  • 6. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.
    Rhee Fv
    Clin Cancer Res; 2007 Mar; 13(5):1353-5. PubMed ID: 17332275
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
    Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
    Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell derived-exosomes: biology and clinical implementations.
    Chaput N; Flament C; Viaud S; Taieb J; Roux S; Spatz A; André F; LePecq JB; Boussac M; Garin J; Amigorena S; Théry C; Zitvogel L
    J Leukoc Biol; 2006 Sep; 80(3):471-8. PubMed ID: 16809645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell Genesys reports long-term survival data in Phase II trial of GVAX.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):245-6. PubMed ID: 12113044
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma.
    Timmerman JM
    Adv Pharmacol; 2004; 51():271-93. PubMed ID: 15464914
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells in cancer immunotherapy.
    Vulink A; Radford KJ; Melief C; Hart DN
    Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell/tumour fusions vaccine.
    Avigan D
    Dev Biol (Basel); 2004; 116():161-8; discussion 179-86. PubMed ID: 15603191
    [No Abstract]   [Full Text] [Related]  

  • 15. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
    Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell immunotherapy for the treatment of neoplastic disease.
    Decker WK; Xing D; Shpall EJ
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines for lymphomas: idiotype vaccines and beyond.
    Houot R; Levy R
    Blood Rev; 2009 May; 23(3):137-42. PubMed ID: 18951668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor.
    Driessens G; Hamdane M; Cool V; Velu T; Bruyns C
    Cancer Res; 2004 Nov; 64(22):8435-42. PubMed ID: 15548715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with dendritic cells for cancer.
    Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
    Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibitive effects of gastric cancer cell-dendritic cell fusion vaccine on tumor cell proliferation cycle].
    Zhang K; Yu PW; Gao PF; Rao Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jul; 9(4):345-8. PubMed ID: 16886121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.